Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

240
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
240
Sustainable Development01:43

Sustainable Development

14.8K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
14.8K
Production Efficiency01:01

Production Efficiency

18.2K
Net production efficiency (NPE) is the efficiency at which organisms assimilate energy into biomass for the next trophic level. Due to low metabolic rates and less energy spent on thermoregulatory processes, the NPE of ectotherms (cold-blooded animals) is 10 times higher than endotherms (warm-blooded animals).
18.2K
Trophic Efficiency00:46

Trophic Efficiency

25.0K
Trophic level transfer efficiency (TLTE) is a measure of the total energy transfer from one trophic level to the next. Due to extensive energy loss as metabolic heat, an average of only 10% of the original energy obtained is passed on to the next level. This pattern of energy loss severely limits the possible number of trophic levels in a food chain.
25.0K
Efficiency of The Carnot Cycle01:16

Efficiency of The Carnot Cycle

3.6K
The hypothetical Carnot cycle consists of an ideal gas subjected to two isothermal and two adiabatic processes. Since the internal energy of an ideal gas depends only on its temperature, which is the same before and after the completion of the Carnot cycle, there is no change in its internal energy. Hence, using the first law of thermodynamics, the total heat exchanged by the ideal gas equals the total work done. Thus, we can quantify the efficiency of the Carnot cycle via the heat exchanged...
3.6K
Turnover Number and Catalytic Efficiency01:19

Turnover Number and Catalytic Efficiency

20.3K
The turnover number of an enzyme is the maximum number of substrate molecules it can transform per unit time. Turnover numbers for most enzymes range from 1 to 1000 molecules per second. Catalase has the known highest turnover number, capable of converting up to 2.8×106 molecules of hydrogen peroxide into water and oxygen per second. Lysozyme has the lowest known turnover number of half a molecule per second.
Chymotrypsin is a pancreatic enzyme that breaks down proteins during digestion....
20.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Clinical Inertia on Implementing Clinical Guideline Recommendations in Patients with Type 2 Diabetes: A Clinician Survey Study.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Surfacic networks.

PNAS nexus·2025
Same author

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2023
Same author

The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.

Clinical pharmacology and therapeutics·2022
Same author

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with <i>Clostridioides difficile</i> infection with and without sepsis.

Therapeutic advances in infectious disease·2022
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 21, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

An Efficient Development Paradigm for Biosimilars.

Christopher J Webster1, Anny C Wong2, Gillian R Woollett3

  • 1BioApprovals, Acton, MA, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|August 8, 2019
PubMed
Summary
This summary is machine-generated.

The current biosimilar development process is inefficient. A new

More Related Videos

Development of Efficient OLEDs from Solution Deposition
07:09

Development of Efficient OLEDs from Solution Deposition

Published on: November 4, 2022

2.7K
Experimental Paradigm for Measuring the Effects of Self-distancing in Young Children
07:01

Experimental Paradigm for Measuring the Effects of Self-distancing in Young Children

Published on: March 1, 2019

8.4K

Related Experiment Videos

Last Updated: Jan 21, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
Development of Efficient OLEDs from Solution Deposition
07:09

Development of Efficient OLEDs from Solution Deposition

Published on: November 4, 2022

2.7K
Experimental Paradigm for Measuring the Effects of Self-distancing in Young Children
07:01

Experimental Paradigm for Measuring the Effects of Self-distancing in Young Children

Published on: March 1, 2019

8.4K

Area of Science:

  • Biopharmaceutical Science
  • Regulatory Science
  • Drug Development

Background:

  • The current biosimilar development paradigm, known as 'totality of evidence' (ToE), is derived from novel drug development.
  • ToE requires extensive analytical, nonclinical, and clinical data, making it burdensome and inefficient.
  • This paradigm does not allow for biosimilarity conclusions based on analytical data alone.

Purpose of the Study:

  • To propose a new, more efficient paradigm for biosimilar development.
  • To introduce the 'confirmation of sufficient likeness' (CSL) approach.
  • To maintain scientific rigor while improving efficiency in biosimilar approvals.

Main Methods:

  • The proposed CSL paradigm emphasizes analytical resemblance between biosimilar candidates and reference products.
  • CSL does not require bridging studies, in vivo nonclinical studies, or powered efficacy studies.
  • This approach relies on comprehensive analytical characterization.

Main Results:

  • Analysis of past biosimilar approvals shows that candidates highly similar in analytical and pharmacokinetic studies have consistently been approved.
  • The CSL approach offers a scientifically rigorous alternative to ToE.
  • The proposed CSL paradigm streamlines the development process.

Conclusions:

  • The 'confirmation of sufficient likeness' (CSL) paradigm offers a more efficient and sustainable pathway for biosimilar development.
  • CSL maintains scientific rigor by focusing on analytical similarity.
  • Adopting CSL can enhance the attractiveness and sustainability of biosimilars as a therapeutic option.